Exploring the molecular pathways of Noncoding RNAs in ovarian cancer: insights into treatment resistance
- 1The Fourth Clinical School of Medicine, Zhejiang Chinese Medical University, Hangzhou First People’s Hospital
- 2School of Medicine, Affiliated Hangzhou First People’s Hospital, Westlake University
Abstract
Ovarian cancer ranks as the third most common gynecological malignancy, yet it has the highest mortality and recurrence rates among all gynecologic cancers. Chemotherapy combined with immunomodulators and targeted agents, including PTX, ADR, PARPi, and platinum-based chemotherapeutics, markedly prolongs progression-free survival of patients with advanced ovarian cancer. Nevertheless, most advanced patients develop acquired drug resistance after long-term chemotherapy, resulting in poor clinical therapeutic efficacy. At present, the detailed mechanisms underlying ovarian cancer chemoresistance have been increasingly elucidated, including enhanced drug efflux, epigenetic modifications, DNA damage repair, apoptosis resistance, and EMT, among others. All the above biological processes are precisely modulated by upstream regulatory molecules, among which ncRNAs, covering miRNAs, lncRNAs and circRNAs, serve as core upstream regulators and exert pivotal functions in tumor malignant progression and chemotherapy resistance. Mechanistically, ncRNAs modulate the resistance via constructing diverse ceRNA competitive regulatory axes and governing canonical drug efflux, cancer stem cell and apoptotic signaling pathways in ovarian cancer. This review systematically summarizes the regulatory roles and molecular networks of ncRNAs in ovarian cancer chemoresistance. Notably, we further highlight the clinical translational potential of ncRNAs: ncRNAs can be applied for patient survival stratification, and act as druggable anti-tumor therapeutic targets to reverse chemoresistance, which provides novel clinical strategies for individualized treatment and curative effect improvement of refractory ovarian cancer.
Related
- Molecular mechanisms of dust-induced lung disease: exploring the role of physicochemical composition and cellular pathways
- Exploring immunotherapy resistance in bone metastasis: mechanisms and optimization of combined treatment strategies-a narrative review.
- Targeted Nanopore Sequencing for Molecular Characterization of First-Line Drug Resistance and Treatment Outcomes Among Patients in the Republic of Congo
- Editorial: Exploring the impact of inflammatory processes on the course of acute myocardial infarction: pathways and therapies
- Metabolic signature of phosphoethanolamine and arginine pathways predicts prognosis and immunotherapy resistance in lung adenocarcinoma
BibTeX
@article{shan2026exploring,
title = {{Exploring the molecular pathways of Noncoding RNAs in ovarian cancer: insights into treatment resistance}},
author = {Weiyan Shan and Jingxia Zhang and Huan Shi and Jie Yu and Qiaoping Xu and Hongkai Shang},
journal = {Journal of Ovarian Research},
year = {2026},
month = aug,
doi = {10.1186/s13048-026-02204-9},
url = {https://doi.org/10.1186/s13048-026-02204-9},
note = {CC BY},
}
RIS
TY - JOUR
TI - Exploring the molecular pathways of Noncoding RNAs in ovarian cancer: insights into treatment resistance
AU - Weiyan Shan
AU - Jingxia Zhang
AU - Huan Shi
AU - Jie Yu
AU - Qiaoping Xu
AU - Hongkai Shang
PY - 2026
DA - 2026/08/01
JO - Journal of Ovarian Research
DO - 10.1186/s13048-026-02204-9
UR - https://doi.org/10.1186/s13048-026-02204-9
AB - Ovarian cancer ranks as the third most common gynecological malignancy, yet it has the highest mortality and recurrence rates among all gynecologic cancers. Chemotherapy combined with immunomodulators and targeted agents, including PTX, ADR, PARPi, and platinum-based chemotherapeutics, markedly prolongs progression-free survival of patients with advanced ovarian cancer. Nevertheless, most advanced patients develop acquired drug resistance after long-term chemotherapy, resulting in poor clinical therapeutic efficacy. At present, the detailed mechanisms underlying ovarian cancer chemoresistance have been increasingly elucidated, including enhanced drug efflux, epigenetic modifications, DNA damage repair, apoptosis resistance, and EMT, among others. All the above biological processes are precisely modulated by upstream regulatory molecules, among which ncRNAs, covering miRNAs, lncRNAs and circRNAs, serve as core upstream regulators and exert pivotal functions in tumor malignant progression and chemotherapy resistance. Mechanistically, ncRNAs modulate the resistance via constructing diverse ceRNA competitive regulatory axes and governing canonical drug efflux, cancer stem cell and apoptotic signaling pathways in ovarian cancer. This review systematically summarizes the regulatory roles and molecular networks of ncRNAs in ovarian cancer chemoresistance. Notably, we further highlight the clinical translational potential of ncRNAs: ncRNAs can be applied for patient survival stratification, and act as druggable anti-tumor therapeutic targets to reverse chemoresistance, which provides novel clinical strategies for individualized treatment and curative effect improvement of refractory ovarian cancer.
SN - 1757-2215
ER -